Learn More
OBJECTIVE To determine whether neuropsychological tests accurately predict incident Alzheimer disease (AD) after 5 and 10 years in participants of the Canadian Study of Health and Aging (CSHA) who were initially nondemented. METHODS The CSHA was conducted in three waves: CSHA-1 (1991 to 1992), CSHA-2 (1996 to 1997), and CSHA-3 (2001 to 2002). The 10-year(More)
We determined whether a battery of neuropsychological tests could predict who would develop Alzheimer's disease (AD) in a group of 123 memory-impaired nondemented patients. Patients were followed longitudinally for 2 years with a research battery of neuropsychological tests. After 2 years, 29 developed probable AD, and 94 did not develop dementia. We used(More)
OBJECTIVE To examine the convergent and, for the first time to our knowledge, the divergent validity of 4 of the subtests of the Mini-Mental State Examination (MMSE): attention, naming, memory, and copy. METHODS Participants included 126 memory-impaired individuals (mean age, 74 years). Because the naming subtest showed no variability, we did not analyze(More)
Neuropathologic confirmation is required to validate the NINCDS-ADRDA Work Group criteria for the clinical diagnosis of Alzheimer's disease (AD). Neuropathologic inclusion and exclusion criteria for AD, however, are not uniform. The purpose of this investigation was to examine the confirmation rate for the Work Group criteria against differing(More)
Given the relationship between the presence of ApoE epsilon 4 and Alzheimer's disease (AD), were studied whether knowledge of epsilon 4 status would predict which memory-impaired patients would develop AD over time. One hundred seven patients who presented with memory impairment but not dementia were referred to the study by their family physicians. These(More)
BACKGROUND Alzheimer disease (AD) and vascular dementia are among the most frequently occurring causes of dementia in the world, and their accurate differentiation is important because different pharmaceutical strategies may modify the course of each disease. OBJECTIVE To determine which of 10 neuropsychological test scores can accurately differentiate(More)
BACKGROUND While neuropsychological deficits have been reported in healthy individuals who use street cannabis, data in patients with multiple sclerosis (MS) are lacking. Given that MS is associated with cognitive deterioration, the aim of this study was to determine the neuropsychological effects of cannabis use in this population. METHODS Two groups,(More)
OBJECTIVE To determine whether the perceptions of patients' cognitive deficits by either the patient or an informant could predict who would develop Alzheimer disease (AD) in a group of 120 memory-impaired patients without dementia. METHODS At entry into the study, patients were assessed by several measures that included neuropsychological tests and the(More)
Multiple arguments for considering routine dementia screening have been presented. Furthermore, dementia diagnoses are widely unrecognized. As a result, persons with dementia are missing important clinical care and treatment interventions. By distinction, the problems of defining, diagnosing, and treating mild cognitive impairment (MCI) are not yet(More)